At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.
Close
CR crane
Post-Mkt 04-14 16:37:26 EDT
193.59
-0.20
-0.10%
盘后194.33
+0.74+0.38%
16:19 EDT
High196.07Low191.63Vol259.69K
Open194.19D1 Closing193.79Amplitude2.29%
Mkt Cap11.15BTradable Cap9.44BTotal Shares57.60M
T/O50.48MT/O Rate0.53%Tradable Shares48.76M
P/B--ROE--EPS0.00
52wk High--52wk Low--P/E--
Dividend--Div.Yield--ROA--

Loading ...

Crane Is Maintained at Hold by Stifel
Dow Jones  ·  04-14 22:23
Crane Is Maintained at Hold by Stifel
Sirtex Medical's DOORwaY90 Study Demonstrates 100% Local Tumor Control with SIR-Spheres®, Setting a New Benchmark in Y-90 for HCC
prnewswire  ·  04-13 21:00
Sirtex Medical's DOORwaY90 Study Demonstrates 100% Local Tumor Control with SIR-Spheres®, Setting a New Benchmark in Y-90 for HCC
Crane Company updates financial calendar for first-quarter earnings release and call
Reuters  ·  04-07
Crane Company updates financial calendar for first-quarter earnings release and call
Crane Company Announces Date for First Quarter 2026 Earnings Release and Teleconference
THOMSON REUTERS  ·  04-07
Crane Company Announces Date for First Quarter 2026 Earnings Release and Teleconference
Press Release: Tempest Reports Year End 2025 Financial Results and Provides Business Update
Dow Jones  ·  03-30
Press Release: Tempest Reports Year End 2025 Financial Results and Provides Business Update
Journal of Urology Publishes ENVISION Trial Results Showing 72.2% 24-Month Duration of Response with ZUSDURI
GlobeNewswire  ·  03-30
Journal of Urology Publishes ENVISION Trial Results Showing 72.2% 24-Month Duration of Response with ZUSDURI
ImmunityBio Lead Bladder Cancer Drug Trial Clears Power Check
Benzinga  ·  03-26
ImmunityBio Lead Bladder Cancer Drug Trial Clears Power Check
Medicus Pharma Business Update Call to Highlight 80% Overall Response Rate (ORR) in Phase 2 SkinJect Study and Agentic AI-enabled Drug Development Plan
GlobeNewswire  ·  03-26
Medicus Pharma Business Update Call to Highlight 80% Overall Response Rate (ORR) in Phase 2 SkinJect Study and Agentic AI-enabled Drug Development Plan
Do Macro Shocks Reveal Hidden Cyclicality In Crane (CR)’s Specialized Technology Story?
Simply Wall St.  ·  03-25
Do Macro Shocks Reveal Hidden Cyclicality In Crane (CR)’s Specialized Technology Story?
Amplia Therapeutics Reports Four Additional Complete Responses and Improved Overall Survival Data in Accent Pancreatic Cancer Trial
GlobeNewswire  ·  03-23
Amplia Therapeutics Reports Four Additional Complete Responses and Improved Overall Survival Data in Accent Pancreatic Cancer Trial
Press Release: Relmada Therapeutics Reports Fourth Quarter and Full Year 2025 Results and Provides Business Update
Dow Jones  ·  03-20
Press Release: Relmada Therapeutics Reports Fourth Quarter and Full Year 2025 Results and Provides Business Update
Moleculin Reports Full Year 2025 Financial Results and Confirms Highly Anticipated 45-Patient Interim Data Unblinding in Pivotal MIRACLE Trial On Track for Mid-2026
GlobeNewswire  ·  03-19
Moleculin Reports Full Year 2025 Financial Results and Confirms Highly Anticipated 45-Patient Interim Data Unblinding in Pivotal MIRACLE Trial On Track for Mid-2026
Crane Company publishes 2025 annual report, net sales rise 8%
Reuters  ·  03-13
Crane Company publishes 2025 annual report, net sales rise 8%
Crane Company announces annual stockholders meeting
Reuters  ·  03-13
Crane Company announces annual stockholders meeting
Protara Therapeutics Announces Fourth Quarter and Full Year 2025 Financial Results and Provides a Business Update
GlobeNewswire  ·  03-10
Protara Therapeutics Announces Fourth Quarter and Full Year 2025 Financial Results and Provides a Business Update
Press Release: enGene Reports First Quarter 2026 Financial Results and Provides Business Update
Dow Jones  ·  03-09
Press Release: enGene Reports First Quarter 2026 Financial Results and Provides Business Update
Relmada Therapeutics Reports 12-Month Phase 2 Interim Data for NDV-01 in Non-Muscle Invasive Bladder Cancer
GlobeNewswire  ·  03-09
Relmada Therapeutics Reports 12-Month Phase 2 Interim Data for NDV-01 in Non-Muscle Invasive Bladder Cancer
Medicus Pharma Reports Positive Phase 2 SKNJCT-003 Topline Data Observing 73% Clinical Clearance and 40% Histological Clearance (CR) at Day 57 in 200μg Cohort
GlobeNewswire  ·  03-05
Medicus Pharma Reports Positive Phase 2 SKNJCT-003 Topline Data Observing 73% Clinical Clearance and 40% Histological Clearance (CR) at Day 57 in 200μg Cohort
Press Release: ORYZON Reports Financial Results and Corporate Update for Quarter Ended December 31st, 2025
Dow Jones  ·  02-28
Press Release: ORYZON Reports Financial Results and Corporate Update for Quarter Ended December 31st, 2025
ZUSDURI™ Achieves Durable Complete Responses Across EORTC Risk Groups in Patients with Recurrent LG-IR-NMIBC
GlobeNewswire  ·  02-27
ZUSDURI™ Achieves Durable Complete Responses Across EORTC Risk Groups in Patients with Recurrent LG-IR-NMIBC

Introduction

Company Name.
crane
Affiliated Markets:
NYSE
Listing Date:
--
Main Business:
Crane NXT, Co. focuses on payment and merchandising technologies. It indents to offer electronic equipment and associated software leveraging extensive, and proprietary core capabilities, including payment verification and authentication, as well as automation solutions, field service solutions, remote diagnostics, and productivity enhancing software solutions. The company is based in Stamford, Connecticut.
Issue price:
--